Analysts give mixed outlooks on ANI Pharmaceuticals stock, with majority bullish

From Nasdaq: 2025-04-11 18:00:00

In the last three months, 6 analysts offered evaluations of ANI Pharmaceuticals (NASDAQ: ANIP), with differing outlooks ranging from bullish to bearish. Recent ratings show 5 bullish, 1 somewhat bullish, and no bearish sentiment. 12-month price targets averaged $87.5, with a high of $94.00 and a low of $80.00, a 2.23% decrease from the previous average. Analyst actions include maintaining, raising, and announcing ratings, reflecting responses to market conditions and company performance. ANI Pharmaceuticals develops, manufactures, and markets generic prescription pharmaceuticals, operating in the United States and Canada. Financial indicators show strong profitability, revenue growth, and debt management. Analysts track 150 firms for stock expectations, relying on financial performance predictions and company communications. Investors can access analyst ratings and stock recommendations through Benzinga Edge.



Read more at Nasdaq: Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)